TY - JOUR
T1 - Photonic Technologies for Liquid Biopsies
T2 - Recent Advances and Open Research Challenges
AU - Dell'Olio, Francesco
AU - Su, Judith
AU - Huser, Thomas
AU - Sottile, Virginie
AU - Cortés-Hernández, Luis Enrique
AU - Alix-Panabières, Catherine
N1 - Funding Information:
F.D. acknowledges funding from the Italian Ministry of Education, University and Research (MIUR) under the “Fondo di finanziamento per le attività base di ricerca (FFABR)” initiative. J.S. acknowledges partial financial support from the NIH R03AG055020, R21MH111109, NSF 1842045, Gordon & Betty Moore Foundation (Grant GBMF7555.14), Flinn Foundation (Grant 26223) Arizona Alzheimer's Consortium, Barrett Cancer Imaging Grant, the Partnership for Clean Competition (2016R2000218G), and the University of Arizona Cancer Center. T.H. acknowledges funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Grant Agreement No. 766181, project “DeLIVER,” as well as by the Deutsche Forschungsgemeinschaft (DFG, German Science Foundation) - project number 415832635. C.A-.P. acknowledges funding from The National Institute of Cancer (INCa, http://www.e-cancer.fr), SIRIC Montpellier Cancer Grant INCa_Inserm_DGOS_12553 and ELBA - Innovative Training Networks (ITN) H2020 - European Liquid Biopsies Academy project - H2020-MSCA-ITN-2017 (http://elba.uni-plovdiv.bg) and the ERA-NET TRANSCAN 2 JTC 2016 PROLIPSY. L.E.C.-H. acknowledges funding from ELBA - Innovative Training Networks (ITN) H2020 - European Liquid Biopsies Academy project - H2020-MSCA-ITN-2017 (http://elba.uni-plovdiv.bg). V.S. acknowledges funding from the Italian Ministry of Education, University and Research (MIUR) to the Department of Molecular Medicine of the University of Pavia under the “Dipartimenti di Eccellenza (2018–2022)” initiative.
Funding Information:
F.D. acknowledges funding from the Italian Ministry of Education, University and Research (MIUR) under the “Fondo di finanziamento per le attività base di ricerca (FFABR)” initiative. J.S. acknowledges partial financial support from the NIH R03AG055020, R21MH111109, NSF 1842045, Gordon & Betty Moore Foundation (Grant GBMF7555.14), Flinn Foundation (Grant 26223) Arizona Alzheimer's Consortium, Barrett Cancer Imaging Grant, the Partnership for Clean Competition (2016R2000218G), and the University of Arizona Cancer Center. T.H. acknowledges funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska‐Curie Grant Agreement No. 766181, project “DeLIVER,” as well as by the Deutsche Forschungsgemeinschaft (DFG, German Science Foundation) ‐ project number 415832635. C.A‐.P. acknowledges funding from The National Institute of Cancer (INCa, http://www.e-cancer.fr ), SIRIC Montpellier Cancer Grant INCa_Inserm_DGOS_12553 and ELBA ‐ Innovative Training Networks (ITN) H2020 ‐ European Liquid Biopsies Academy project ‐ H2020‐MSCA‐ITN‐2017 ( http://elba.uni-plovdiv.bg ) and the ERA‐NET TRANSCAN 2 JTC 2016 PROLIPSY. L.E.C.‐H. acknowledges funding from ELBA ‐ Innovative Training Networks (ITN) H2020 ‐ European Liquid Biopsies Academy project ‐ H2020‐MSCA‐ITN‐2017 ( http://elba.uni-plovdiv.bg ). V.S. acknowledges funding from the Italian Ministry of Education, University and Research (MIUR) to the Department of Molecular Medicine of the University of Pavia under the “Dipartimenti di Eccellenza (2018–2022)” initiative.
Publisher Copyright:
© 2020 Wiley-VCH GmbH
PY - 2021/1
Y1 - 2021/1
N2 - The recent development of sophisticated techniques capable of detecting extremely low concentrations of circulating tumor biomarkers in accessible body fluids, such as blood or urine, could contribute to a paradigm shift in cancer diagnosis and treatment. By applying such techniques, clinicians can carry out liquid biopsies, providing information on tumor presence, evolution, and response to therapy. The implementation of biosensing platforms for liquid biopsies is particularly complex because this application domain demands high selectivity/specificity and challenging limit-of-detection (LoD) values. The interest in photonics as an enabling technology for liquid biopsies is growing owing to the well-known advantages of photonic biosensors over competing technologies in terms of compactness, immunity to external disturbance, and ultrahigh spatial resolution. Some encouraging experimental results in the field of photonic devices and systems for liquid biopsy have already been achieved by using fluorescent labels and label-free techniques and by exploiting super-resolution microscopy, surface plasmon resonance, surface-enhanced Raman scattering, and whispering gallery mode resonators. The current state-of-the-art is critically reviewed here, starting from the requirements imposed by the detection of the most common circulating biomarkers. Open research challenges are considered together with competing technologies, and the most promising paths of improvement are discussed for future applications.
AB - The recent development of sophisticated techniques capable of detecting extremely low concentrations of circulating tumor biomarkers in accessible body fluids, such as blood or urine, could contribute to a paradigm shift in cancer diagnosis and treatment. By applying such techniques, clinicians can carry out liquid biopsies, providing information on tumor presence, evolution, and response to therapy. The implementation of biosensing platforms for liquid biopsies is particularly complex because this application domain demands high selectivity/specificity and challenging limit-of-detection (LoD) values. The interest in photonics as an enabling technology for liquid biopsies is growing owing to the well-known advantages of photonic biosensors over competing technologies in terms of compactness, immunity to external disturbance, and ultrahigh spatial resolution. Some encouraging experimental results in the field of photonic devices and systems for liquid biopsy have already been achieved by using fluorescent labels and label-free techniques and by exploiting super-resolution microscopy, surface plasmon resonance, surface-enhanced Raman scattering, and whispering gallery mode resonators. The current state-of-the-art is critically reviewed here, starting from the requirements imposed by the detection of the most common circulating biomarkers. Open research challenges are considered together with competing technologies, and the most promising paths of improvement are discussed for future applications.
KW - liquid biopsies
KW - oncologyoptical microscopy
KW - plasmonics
KW - whispering gallery modes
UR - http://www.scopus.com/inward/record.url?scp=85097010169&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097010169&partnerID=8YFLogxK
U2 - 10.1002/lpor.202000255
DO - 10.1002/lpor.202000255
M3 - Review article
AN - SCOPUS:85097010169
SN - 1863-8880
VL - 15
JO - Laser and Photonics Reviews
JF - Laser and Photonics Reviews
IS - 1
M1 - 2000255
ER -